Table 4.
Crude and Adjusted Hazards for Events During Follow‐up for 997 Nonresponders to IFN plus RBV Compared With 628 Responders
| Univariate Analysisa | Multivariate Analysisa, b | |||
|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Overall deaths | 0.35 (0.24‐0.52) | <0.001 | 0.36 (0.24‐0.54) | <0.001 |
| sHR (95% CI) | P Value | sHR (95% CI) | P Value | |
| Cause‐specific deaths | ||||
| Liver‐related deaths | 0.12 (0.05‐0.28) | <0.001 | 0.13 (0.06‐0.28) | <0.001 |
| Non‐liver‐related deaths | 0.69 (0.43‐1.1) | 0.119 | 0.73 (0.44‐1.20) | 0.214 |
| AIDS‐related deaths | 0.45 (0.09‐2.22) | 0.325 | 0.37 (0.09‐1.43) | 0.148 |
| NLR‐NAR deaths | 0.73 (0.44‐1.19) | 0.204 | 0.79 (0.47‐1.35) | 0.388 |
| New AIDS‐defining events | 0.34 (0.16‐0.72) | 0.004 | 0.37 (0.17‐0.79) | 0.010 |
| Liver‐related events | ||||
| Liver decompensation | 0.09 (0.04‐0.2) | <0.001 | 0.10 (0.05‐0.21) | <0.001 |
| HCC | 0.12 (0.03‐0.5) | 0.004 | 0.13 (0.03‐0.50) | 0.003 |
| LT | 0.10 (0.01‐0.77) | 0.027 | 0.12 (0.02‐0.78) | 0.027 |
| NLR‐NAR events | ||||
| Diabetes mellitusc | 0.54 (0.34‐0.87) | 0.011 | 0.57 (0.35‐0.93) | 0.024 |
| NLR‐NAR cancer | 0.91 (0.6‐1.38) | 0.650 | 0.91 (0.58‐1.45) | 0.703 |
| Cardiovascular events | 1.41 (0.93‐2.13) | 0.105 | 1.57 (0.99‐2.50) | 0.056 |
| NAR infections | 0.55 (0.33‐0.92) | 0.024 | 0.65 (0.37‐1.14) | 0.131 |
| Bone events | 1.39 (0.82‐2.35) | 0.225 | 1.28 (0.69‐2.38) | 0.433 |
| Renal eventsc | 0.41 (0.17‐0.99) | 0.049 | 0.43 (0.17‐1.09) | 0.075 |
Cox regression analysis was performed to compare the HR of overall death between responders and nonresponders. Fine and Gray regression analysis was performed to compare the HR of events in the presence of competing risks.
Adjusted for age, sex, previous AIDS‐defining conditions (yes vs. no), HIV transmission category (injection drug users vs. non–injection drug users), nadir CD4+ cell count, cART (yes vs. no), undetectable HIV RNA at baseline (yes vs. no), FIB4 ≥3.25 (yes vs. no), genotype (3 vs. other genotypes), and exposure to abacavir, didanosine, indinavir, and lopinavir: lower than or equal to the median cumulative exposure in years versus higher than the median cumulative exposure.
Excluding 47 and 4 patients with diabetes mellitus and chronic renal failure at baseline, respectively.